Form 8-K - Current report:
SEC Accession No. 0001213900-25-000517
Filing Date
2025-01-03
Accepted
2025-01-03 08:31:16
Documents
14
Period of Report
2025-01-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0226709-8k_oramed.htm   iXBRL 8-K 30037
2 DEFERRAL AND CONSENT UNDER TRANCHE B SENIOR SECURED CONVERTIBLE NOTE, DATED JANU ea022670901ex10-1_oramed.htm EX-10.1 63319
  Complete submission text file 0001213900-25-000517.txt   284322

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ormp-20250102.xsd EX-101.SCH 3009
4 XBRL LABEL FILE ormp-20250102_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ormp-20250102_pre.xml EX-101.PRE 22355
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0226709-8k_oramed_htm.xml XML 3688
Mailing Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 646-844-1164
ORAMED PHARMACEUTICALS INC. (Filer) CIK: 0001176309 (see all company filings)

EIN.: 980376008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35813 | Film No.: 25503821
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)